PITTIE GROUP
Charged with a force of dynamism and enterprise, the Pittie Group is a growing Indian Group of companies, headquartered in Mumbai. Known for its success in the establishment, building and nurturing of diverse brands, the company has also become synonymous with the creation of niche markets for itself in sectors ranging across the industries of Real Estate, FMCG Distribution, Media (Broadcasting) & Entertainment, Quick Service Restaurants (QSR) and E-commerce. Founded in 1991, by Mr. Krishna Kumar Pittie, the Group has managed to build a remarkable name for itself across the country. At its core, the company thrives for Innovation and Quality.
PITTIE GROUP
Industry:
Real Estate
Founded:
1991-01-01
Address:
Mumbai, Maharashtra, India
Country:
India
Website Url:
http://www.pittiegroup.com
Total Employee:
51+
Status:
Active
Contact:
+912242604260
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Font API WordPress Content Delivery Network LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Fossbytes
Fossbytes is one of the fastest growing tech media startups of India.
Kanmo Retail Group
The Group's has interests across Asia in industry, trading, real estate and financial markets.
VGN Property Developers
VGN Property Developers is a Multi-Million dollar real estate company headquartered in Chennai.
Current Advisors List
Founder
Official Site Inspections
http://www.pittiegroup.com Semrush global rank: 6.04 M Semrush visits lastest month: 1.15 K
Unable to get host informations!!!
More informations about "Pittie Group"
Partners & Licensees - REGENXBIO
In addition to our own clinical programs, REGENXBIO has enabled the development of gene therapies based on the NAV® Technology platform across a broad range of therapeutic areas …See details»
Companies Enter Licensing Agreements to Expand Gene Therapy ... - BioSpace
Oct 12, 2021 Days after forging a $1.1 billion agreement with Selecta Biosciences to develop gene therapies for lysosomal storage disorders, Takeda Pharmaceutical entered into a …See details»
Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene ...
Jul 21, 2025 Vector backbone platforms developed by CDMOs are reshaping gene therapy development by offering speed, scalability, and regulatory readiness while pushing the field …See details»
FDA's new platform guidance aims to smooth regulatory …
The FDA has new guidance on requesting a platform designation that can smooth subsequent applications for biotechs working off the same technology.See details»
Selecta Biosciences and Takeda Announce Gene Therapy Platform Licensing ...
Oct 4, 2021 Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders. Selecta Bioscience, a biotechnology company specializing in …See details»
Biopharma Therapeutics Licensing and Venture Deals - J.P. Morgan
Cell and gene therapy venture round averages are steady despite lower overall activity Biopharma companies developing advanced cell and gene therapies have increasingly attracted a larger …See details»
Industry shows trust in cell and gene therapy platform ... - Nature
Nov 24, 2022 Cell and gene therapy companies continue to attract large deals in 2022, despite the financing landscape looking gloomier than in the previous year.See details»
MaxCyte and Kamau Therapeutics sign platform license agreement
Sep 17, 2024 MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.See details»
Cell and gene therapy at GenScript Biotech Global Forum
Feb 24, 2025 Cell and gene therapy development, manufacturing, and investment leaders gathered at the 2025 GenScript Biotech Global Forum to discuss challenges in the field.See details»
New FDA Designations May Jumpstart Gene Therapy Development
Oct 18, 2024 New FDA designations granted for rare disease therapies provide incentives for companies to further develop treatments.See details»
MaxCyte signs strategic platform license with Kamau …
Sep 23, 2024 Bringing this groundbreaking gene therapy research into the clinic requires a robust manufacturing process and the ability to scale,” Maher Masoud, President and CEO, …See details»
Voyager Therapeutics Announces Pfizer License of Next …
CAMBRIDGE, Mass. October 4, 2022 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation …See details»
MaxCyte Signs Strategic Platform License with Kamau ... - BioSpace
Sep 16, 2024 Our ExPERT™ platform, which is based on our Flow Electroporation ® technology, has been designed to support the rapidly expanding cell therapy market and can …See details»
JCR Pharmaceuticals Signs Licensing Agreement with …
Jul 11, 2025 Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca's (NASDAQ: AZN) rare disease subsidiary Alexion for …See details»
U.S. FDA Grants Platform Technology Designation to the Viral …
Jun 4, 2025 U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular …See details»
Overview of the Regulatory Path to Commercializing a Gene Therapy
Sep 20, 2018 Successful Gene Therapy Regulatory Strategies A successful gene therapy regulatory strategy requires: new product and process validation strategies to accommodate …See details»
Dyno Therapeutics Forms New Strategic Partnership With Roche …
Oct 24, 2024 New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets Dyno to …See details»
Adding State Licensing to Your Cell and Gene Launch Strategy
May 27, 2021 We know that the cell and gene therapy market is growing. In Q1 of this year, a report was released stating that the market is projected to reach $25 billion by 2027 and …See details»
Novartis, Voyager Therapeutics reach license option agreement …
Basel, March 8, 2022 — Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus …See details»
Optimizing AAV Gene Delivery: Hitting the Target Safely and …
Feb 3, 2025 Cargo-specific technologies include miQURE, a single gene silencing platform, LinQURE that provides multiple gene-silencing microRNAs in a single AAV, and GoQURE that …See details»